NASDAQ:AZRX - AzurRx BioPharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.48 +0.04 (+1.64 %) (As of 01/22/2019 04:00 PM ET)Previous Close$2.44Today's Range$2.36 - $2.5252-Week Range$1.00 - $3.76Volume58,600 shsAverage Volume77,279 shsMarket Capitalization$42.01 millionP/E RatioN/ADividend YieldN/ABeta1.54 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York. Receive AZRX News and Ratings via Email Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AZRX Previous Symbol CUSIPN/A Webwww.azurrx.com Phone646-699-7855Debt Debt-to-Equity RatioN/A Current Ratio3.89 Quick Ratio3.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book17.71Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,090,000.00 Net MarginsN/A Return on Equity-301.71% Return on Assets-154.70%Miscellaneous Employees13 Outstanding Shares16,940,000Market Cap$42.01 million OptionableNot Optionable AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions What is AzurRx BioPharma's stock symbol? AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX." What price target have analysts set for AZRX? 3 brokerages have issued 1 year target prices for AzurRx BioPharma's stock. Their predictions range from $6.00 to $8.00. On average, they anticipate AzurRx BioPharma's share price to reach $6.6667 in the next year. This suggests a possible upside of 168.8% from the stock's current price. View Analyst Price Targets for AzurRx BioPharma. What is the consensus analysts' recommendation for AzurRx BioPharma? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AzurRx BioPharma. Has AzurRx BioPharma been receiving favorable news coverage? News articles about AZRX stock have trended very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AzurRx BioPharma earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. Who are some of AzurRx BioPharma's key competitors? Some companies that are related to AzurRx BioPharma include Constellation Pharmaceuticals (CNST), Ocular Therapeutix (OCUL), AcelRx Pharmaceuticals (ACRX), Molecular Templates (MTEM), Nature's Sunshine Products (NATR), CytoDyn (CYDY), MOTIF BIO PLC/S (MTFB), Emisphere Technologies (EMIS), Poxel (PXXLF), REDHILL BIOPHAR/S (RDHL), Bellicum Pharmaceuticals (BLCM), Millendo Therapeutics (MLND), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX) and Spero Therapeutics (SPRO). Who are AzurRx BioPharma's key executives? AzurRx BioPharma's management team includes the folowing people: Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)Mr. Daniel Dupret, Chief Scientific Officer (Age 63)Dr. Mathieu Schué Ph.D., Head of LaboratoryDr. James E. Pennington, Chief Medical Officer (Age 76) When did AzurRx BioPharma IPO? (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities served as the underwriters for the IPO. How do I buy shares of AzurRx BioPharma? Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AzurRx BioPharma's stock price today? One share of AZRX stock can currently be purchased for approximately $2.48. How big of a company is AzurRx BioPharma? AzurRx BioPharma has a market capitalization of $42.01 million. AzurRx BioPharma employs 13 workers across the globe. What is AzurRx BioPharma's official website? The official website for AzurRx BioPharma is http://www.azurrx.com. How can I contact AzurRx BioPharma? AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected] MarketBeat Community Rating for AzurRx BioPharma (NASDAQ AZRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 119 (Vote Outperform)Underperform Votes: 80 (Vote Underperform)Total Votes: 199MarketBeat's community ratings are surveys of what our community members think about AzurRx BioPharma and other stocks. Vote "Outperform" if you believe AZRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AZRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/22/2019 by MarketBeat.com StaffFeatured Article: What is a Swap?